ORKA
NASDAQOruka Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
Price$71.99+1.13 (+1.59%)
05:00 PM07:45 PM
News · 26 weeks64-73%
2026-04-262026-10-18
Mix2790d
- Insider17(63%)
- SEC Filings6(22%)
- Other2(7%)
- Offering1(4%)
- Leadership1(4%)
Latest news
25 items- INSIDERSEC Form 4 filed by Oruka Therapeutics Inc.4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSEC Form 4 filed by Oruka Therapeutics Inc.4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERChief Executive Officer Klein Lawrence Otto exercised 25,000 shares at a strike of $7.80 and sold $2,090,593 worth of shares (25,000 units at $83.62) as part of a pre-agreed trading plan (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- PROruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional DosingPASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4 Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001 ORKA-001 maintained a favorable safety and tolerability profile through Week 28 52-week EVERLAST-A data for all patients expected in December 2026 16-week EVERLAST-B data expected in 4Q 2026 MENLO PARK, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppura
- INSIDERSenior Vice President, Finance Agarwal Arjun sold $51,035 worth of shares (533 units at $95.75) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 14,219 units (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERGeneral Counsel Quinlan Paul T exercised 10,000 shares at a strike of $7.80 and sold $936,417 worth of shares (10,000 units at $93.64) as part of a pre-agreed trading plan (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERChief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $734,145 worth of shares (7,947 units at $92.38) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 31,771 units (SEC Form 4) (for tax liability)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSenior Vice President, Finance Agarwal Arjun sold $926,010 worth of shares (10,019 units at $92.43) as part of a pre-agreed trading plan and exercised 9,459 shares at a strike of $15.88, decreasing direct ownership by 4% to 14,752 units (SEC Form 4) (for tax liability)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERChief Executive Officer Klein Lawrence Otto sold $234,681 worth of shares (2,452 units at $95.71), decreasing direct ownership by 0.26% to 923,128 units (SEC Form 4) to cover withholding tax4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERGeneral Counsel Quinlan Paul T sold $99,443 worth of shares (1,039 units at $95.71), decreasing direct ownership by 3% to 29,995 units (SEC Form 4) to cover withholding tax4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERChief Operating Officer Sandler Laura Lee sold $86,713 worth of shares (906 units at $95.71), decreasing direct ownership by 0.38% to 235,478 units (SEC Form 4) (withholding tax)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- PROruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare ConferenceMENLO PARK, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis and hidradenitis suppurativa, today announced its attendance at the 2026 Morgan Stanley Global Healthcare Conference, taking place in New York, NY from September 14-16, 2026.About Oruka TherapeuticsOruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from inflammatory diseases like plaque psoriasis and hidr
- INSIDERChief Operating Officer Sandler Laura Lee exercised 5,000 shares at a strike of $7.80 and sold $459,101 worth of shares (5,000 units at $91.82) as part of a pre-agreed trading plan (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERChief Executive Officer Klein Lawrence Otto exercised 75,000 shares at a strike of $7.80 and sold $6,887,484 worth of shares (75,000 units at $91.83) as part of a pre-agreed trading plan (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- SECSEC Form 424B5 filed by Oruka Therapeutics Inc.424B5 - Oruka Therapeutics, Inc. (0000907654) (Filer)
- SECSEC Form EFFECT filed by Oruka Therapeutics Inc.EFFECT - Oruka Therapeutics, Inc. (0000907654) (Filer)
- INSIDERChief Commercial Officer Edwards Larry Todd was granted 100,000 shares (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSEC Form 3 filed by new insider Edwards Larry Todd3 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- SECOruka Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Oruka Therapeutics, Inc. (0000907654) (Filer)
- PROruka Therapeutics Appoints Todd Edwards as Chief Commercial OfficerMENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced the appointment of Todd Edwards as Chief Commercial Officer, effective August 24, 2026. Mr. Edwards brings more than 25 years of commercial leadership experience across immunology and dermatology, spanning both biologics and topical therapies. He joins Oruka from Arcutis Biotherapeutics, Inc., where he served as Executive Vice President and Chief Commercial Officer a
- SECSEC Form S-3 filed by Oruka Therapeutics Inc.S-3 - Oruka Therapeutics, Inc. (0000907654) (Filer)
- INSIDERChief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $782,882 worth of shares (7,000 units at $111.84) as part of a pre-agreed trading plan (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERGeneral Counsel Quinlan Paul T exercised 52,000 shares at a strike of $11.60 and sold $5,641,409 worth of shares (52,000 units at $108.49) as part of a pre-agreed trading plan (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- INSIDERSenior Vice President, Finance Agarwal Arjun exercised 10,000 shares at a strike of $15.69 and sold $1,066,572 worth of shares (10,000 units at $106.66) as part of a pre-agreed trading plan (SEC Form 4)4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)
- SECSEC Form 10-Q filed by Oruka Therapeutics Inc.10-Q - Oruka Therapeutics, Inc. (0000907654) (Filer)
ORKA FAQ
5 questionsWhere does ORKA stock trade?
Oruka Therapeutics Inc. (ORKA) is listed on NASDAQ.What sector and industry is ORKA in?
Oruka Therapeutics Inc. operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.What are analysts saying about ORKA?
Oruka Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Piper Sandler: Overweight on 2025-12-18. Recent price targets range from $2000.00 to $4900.00.What companies are similar to ORKA?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), NEOG (Neogen Corporation), CLDX (Celldex Therapeutics Inc.). Compare ORKA side-by-side with any of them on Quantisnow.How can I track ORKA on Quantisnow?
Quantisnow aggregates Oruka Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ORKA to receive live email and push alerts on every new disclosure.